Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California.
Krish Krishnan, Chairman and Chief Executive Officer, will represent the Company in a session scheduled at 10:40 am PDT on Wednesday, June 15.
A live webcast of the presentation will be available here and on the Investor section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.
CONTACTS:
Investors and Media:
Meg Dodge
Krystal Biotech
This email address is being protected from spambots. You need JavaScript enabled to view it.
Source: Krystal Biotech, Inc.
| Last Trade: | US$190.23 |
| Daily Change: | 1.90 1.01 |
| Daily Volume: | 272,138 |
| Market Cap: | US$5.510B |
October 14, 2025 September 15, 2025 September 02, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
